Subject: Something About Diabetes. Dec. 31, 2007.
Here is something that I found about Diabetes.
............................................................
............................................................
Diabetes Type 2 is Curable
Letter Nexus Dec 2006
Dear Duncan: I am writing to encourage everyone to read
two recent NEXUS articles: the obesity article by David
Zeoli (vol. 13, no. 5) and
http://www.whale.to/a/smith.html
"The Deadly Diabetes Deception" by Thomas Smith (vol. 11,
no. 4; also see his website at
http://www.%20healingmatters%20.com
I developed diabetes type 2 about two-and-a-half years
ago. I was in a mess.
I saw my GP and then a specialist, who diagnosed me as a
chronic diabetic. I was put on two types of prescription
medication.
I was constantly told by our leading diabetes institution
that diabetes type 2 is incurable. This is not the case.
After putting the facts together and understanding the
problem, you can actually do something about diabetes type
2. I did, and I want to let others know.
Diabetes type 2 isn't a problem of dealing with sugars,
but a problem of dealing with fats and oils. Back in 1920,
only two per 100,000 had this disease.
Now there are 16,000 per 100,000, and this may be a
conservative figure. Back in the 1920s there were plenty of
sugary sweets around, but the oils and fats weren't
engineered. You cooked with lard, butter or dripping.
Instead of submitting to taking these drugs to keep this
disease under control for the rest of my life, I read the
"Diabetes Deception" article in NEXUS and put it into
motion.
I asked my endocrinologist if anyone had cured themselves
of diabetes type 2.
He said "only once", because that person had gone off
their unrelated medication and their diabetes disappeared.
I said I wanted to be the first one to cure it
intentionally. He said I had to pass the blood glucose
tolerance test and had to have blood sugar levels of less
than six for the last three months.
Within eight months, I passed both tests. The
endocrinologist asked how I did it. I told him of Thomas
Smith's research and how nearly anyone can do what I had
just done. He wasn't interested.
I approached Diabetes Australia about my success, and in the meantime
got
an
article published in Better Homes and Gardens' Diabetic Living magazine.
Of
the
40 or so replies I received, six went on the diet I proposed. Those six
were
thrilled with their results.
I find it hard to get the truth out there, that diabetes
type 2 is curable in about 80 per cent of cases. Diabetes
Australia didn't want to publish my article. They believe
that diabetes type 2 is not curable. They believe that once
you have it under control, that's as good as it gets.
I wrote to our Federal Health Minister, telling him about
being able to arrest the diabetes type 2 pandemic we now
have in Australia. I received an email saying how pleasing
it was that I had the disease "under control", and how much
money they were spending on it.
In the USA, Thomas Smith has found the same problems in
getting the word out about successful treatments for
diabetes type 2.
Cheers,Tony Hall,
yvettemhall@[EMAIL PROTECTED]
Winston. johnfw@[EMAIL PROTECTED]
Zyprexa: A Prescription for Diabetes, Disease and Early
D-ath
by Leonard Roy Frank
There were 20 de-ths, including 12 suicides, in the
http://www.whale.to/a/zyprexa_h.html
Shockingly, these deat-s went unre****ted in the
scientific literature. The deat- cover-ups also took place
in re****ting trial results of several other atypical
antipsychotics. These -eaths occurred during very short
trial periods, so the F-A's approval of these d-ugs is
appalling.
On June 8, 2005, Eli Lilly & Co. announced that it had
agreed to pay $690 million to settle some 8,000 lawsuits
filed by people who re****ted that taking the antipsychotic
dr-g Zyprexa resulted in unwanted weight gain, diabetes,
other metabolic diseases, and de-th.
Zyprexa, Lilly's top-selling drug, is used in the
treatment of schizophrenia and in the short-term treatment
of manic episodes associated with bipolar disorder. More
than 2,500 other claimants refused to participate in the
settlement, presumably in the belief that the amount
received by each claimant, $62,500 on average, was
insufficient compensation for the pain and suffering
Zyprexa caused them.
On July 21, Eli Lilly came out with its second-quarter
financial re****t showing that $1.07 billion was allocated
to cover its liabilities in these lawsuits. That amount
exceeded the $690 million settlement by $380 million.
The additional sum was the company's estimate of its
liability and defense costs for the unsettled claims
[re****ted in Forbes.com, July 21, 2005]. News of the
settlement may generate more damage claims, in which event
the cost to Eli Lilly may be greater than the $1.07 billion
already set aside.
According to Eli Lilly, about 17 million people in 86
countries have taken Zyprexa since its introduction in
1996. Although there is no way of accurately estimating the
number of Zyprexa's victims, it's safe to say that this
d-ug has caused diabetes and other diseases in millions of
people, and that tens of thousands of people have d-ed or
will di- prematurely.
Despite these facts, the media has paid scant attention
to the settlement.
Despite these facts, there hasn't been a single voice of
outrage or protest heard in the halls of C-ngress or on the
evening news. And despite these facts, Eli Lilly has made
no special effort to warn the public of the potentially
disastrous consequences of taking Zyprexa as it continues
to rake in profits from the sale of this dr-g.
Zyprexa, whose generic name is olanzapine, belongs to a
class of psychiatric dru-s known as atypical
antipsychotics. Others in this class are Novartis' Clozaril
(clozapine), Janssen's Risperdal (risperidone),
AstraZeneca's Seroquel (quetiapine), Bristol-Myers Squibb's
Abilify (aripiprazole), and Pfizer's Geodon (ziprasidone).
The first atypical antipsychotic, Clozaril, came on the
market in 1990. The manufacturers hailed these d-ugs as
more effective and safer than the conventional
antipsychotics such as Thorazine (chlorpromazine), Haldol
(haloperidol), and Navane (thiothixene), which have been
available since the 1950s.
Following expensive marketing and promotional campaigns
by the manufacturers of the atypicals, belief in their
unsubstantiated claims became widespread, with the result
that the companies were able to charge much more for the
newer drugs than were being charged for the older ones.
Today, a month's supply of Zyprexa costs about $380, 10-30
times more expensive than a month's supply of a
conventional antipsychotic.
Total worldwide sales for the antipsychotics have grown
from less than $500 million in 1993 (almost all
conventional antipsychotics) to more than $14 billion in
2004 (all but $1 billion of which came from atypical
antipsychotics).
For more than 10 years, the drug companies have
consistently downplayed some of the serious risks
associated with taking atypical antipsychotic dru-s.
Psychiatrist E. Fuller Torrey, a leading proponent of
drug therapy for schizophrenics, has written about one of
the techniques used to mislead physicians and the public:
"Psychiatrists trying to evaluate schizophrenia d-ugs are
not told that the expert who minimizes the side effects of
Zyprexa receives a $10,000 retainer from Eli Lilly and also
owns substantial company stock." American Prospect, July
15, 2002.
Faced with mounting evidence of their harmfulness, the
Food and D-ug Administration (FD-) finally required, in
2003, all manufacturers of the atypicals to place on their
labels a warning about the increased risk of diabetes for
users of these dr-gs.
Hersh and Hersh, a San Francisco law firm representing
some 400 of the claimants in the recent settlement, charged
that Eli Lilly "fraudulently withheld relevant information
from potential users of Zyprexa" before 2003.
Eli Lilly, went the charge, failed to warn doctors and
patients that Zyprexa carried terrible and potentially
lethal risks from weight gain and diabetes, which the
company knew or should have known.
Such warnings might have led doctors to lower dosage
levels in prescribing Zyprexa and to regularly test the
blood-sugar levels of their Zyprexa patients. They might
even have caused some doctors to stop prescribing the dr-g.
Part 1.
John Winston.
|
